8 Oct 2020

ENPICOM is now a corporate sponsor of The Antibody Society

ENPICOM is now a corporate sponsor of The Antibody Society

October 8, 2020

The Antibody Society is an international non-profit association, founded in 2007, to represent individuals and organizations involved in antibody-related research and development. Since the very beginning, ENPICOM has been embedded in the Society’s Adaptive Immune Receptor Repertoire (AIRR) Community. The AIRR community is a research-driven group that coordinates stakeholders in the use of next-generation sequencing technologies to study B and T cell receptor repertoires. Two prominent members of the AIRR community serve on ENPICOM’s scientific advisory board.

ENPICOM has always supported the Society’s values and recognizes the need for life scientists to have efficient tools to deepen their knowledge of the immune system and drive faster, more efficient therapeutic discovery and development. We are now pleased to announce an official corporate sponsorship of The Antibody Society.

According to Jos Lunenberg, CEO and co-founder of ENPICOM, the partnership is a natural outgrowth of the company’s support for novel therapeutic discovery processes: “ENPICOM is continuously innovating to support life scientists with groundbreaking solutions. We are proud to be involved and support the growth of the antibody development community. This formal sponsorship demonstrates ENPICOM’s strong commitment to supporting the scientific community.”

Enhancing antibody discovery with Rep-Seq

 

Monoclonal antibodies (mAbs) are one of the major therapeutic strategies to treat a variety of diseases, including cancer, infectious diseases, and autoimmunity. Antibody discovery is a laborious process, that critically depends on the screening of antibodies to determine antigen specificity and other therapeutic characteristics. Genetic information captured in antibody repertoires greatly improves the antibody discovery process and is becoming increasingly important for candidate selection. All the widely applied antibody isolation technologies leverage Rep-Seq data in a unique way, with the aim to increase the depth of the analysis and improve the accuracy of their candidate selection. Analysis of properties like affinity maturation and sequence diversity using phylogenetic analysis and clone tracking drives the characterization process, thereby accelerating the discovery of monoclonal antibodies.

ENPICOM focuses on decoding the immune system and its products and services for diagnostics, life sciences, and biopharmaceutical industry allow researchers to easily manage, visualize, interrogate, and interpret complex immune repertoire data.

Want to know more?

 

Would you like to learn more about our innovative immunomics data handling solutions? Talk to our experts to discuss your advanced analysis needs and see how you can make the most out of your immune repertoire sequencing data today.